LENZ Therapeutics (LENZ) Expected to Announce Earnings on Thursday

LENZ Therapeutics (NASDAQ:LENZ) is anticipated to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.97) per share and revenue of $4.20 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.03. The firm had revenue of $5.49 million during the quarter, compared to the consensus estimate of $2.38 million. On average, analysts expect LENZ Therapeutics to post ($4.10) EPS for the current fiscal year and ($2.80) EPS for the next fiscal year.

LENZ Therapeutics Stock Up 0.3%

Shares of LENZ stock opened at $3.15 on Wednesday. The business has a 50 day moving average of $4.16 and a two-hundred day moving average of $8.28. The company has a market cap of $98.97 million, a P/E ratio of -0.77 and a beta of 0.64. LENZ Therapeutics has a 52 week low of $3.06 and a 52 week high of $32.13.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on LENZ shares. Citigroup reiterated a “buy” rating on shares of LENZ Therapeutics in a research report on Wednesday, August 12th. Zacks Research raised shares of LENZ Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. HC Wainwright reiterated a “buy” rating on shares of LENZ Therapeutics in a report on Tuesday, July 7th. Weiss Ratings lowered shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 9th. Finally, Piper Sandler dropped their target price on LENZ Therapeutics from $7.00 to $5.00 and set a “neutral” rating on the stock in a report on Monday, October 19th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, LENZ Therapeutics currently has an average rating of “Hold” and an average price target of $23.00.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for the treatment of presbyopia, the age-related loss of near vision. The company is headquartered in San Diego, California, and its programs are designed to provide an alternative to reading glasses and other corrective lenses.

LENZ’s primary product candidate is aceclidine ophthalmic solution, developed under the names LNZ100 and VIZZ. The pupil-selective miotic is intended to improve near vision while preserving distance vision, without relying on the lens-shaping mechanism targeted by some other presbyopia treatments.